



## RSC Communicable and Respiratory Disease Report for England

### Key Statistics:

Week Number/Year.....	13/2024
Week Starting - Ending.....	25/03/2024 - 31/03/2024
No. of Practices.....	1,654
Population.....	16,953,027

### National (England)

- **Acute Respiratory Infections:** decreased from **346.8** in week 12 to **271.2** in week 13.
- **Influenza-like illness:** decreased from **4.9** in week 12 to **3.4** in week 13.
- **Exacerbations of Chronic Lung Disease:** decreased from **14.4** in week 12 to **12.0** in week 13.
- **Lower Respiratory Tract Infections:** decreased from **120.4** in week 12 to **98.8** in week 13.
- **Upper Respiratory Tract Infections:** decreased from **220.0** in week 12 to **169.0** in week 13.
- **COVID-19:** decreased from **1.6** in week 12 to **1.0** in week 13.

### Regional (North, South, London and Midlands and East)

- **Acute Respiratory Infections:** decreased from **261.2** in week 12 to **203.8** in week 13 in the London region, decreased from **400.8** in week 12 to **325.2** in week 13 in the North region, decreased from **332.3** in week 12 to **259.0** in week 13 in the South region, and decreased from **379.3** in week 12 to **287.4** in week 13 in the Midlands And East region.
- **Influenza-like illness:** decreased from **4.5** in week 12 to **3.0** in week 13 in the London region, decreased from **4.8** in week 12 to **3.2** in week 13 in the North region, decreased from **5.3** in week 12 to **3.7** in week 13 in the South region, and decreased from **4.8** in week 12 to **3.5** in week 13 in the Midlands And East region.
- **Exacerbations of Chronic Lung Disease:** decreased from **9.1** in week 12 to **6.6** in week 13 in the London region, decreased from **19.3** in week 12 to **16.8** in week 13 in the North region, decreased from **13.0** in week 12 to **10.8** in week 13 in the South region, and decreased from **15.5** in week 12 to **13.0** in week 13 in the Midlands And East region.
- **Lower Respiratory Tract Infections:** decreased from **70.4** in week 12 to **57.6** in week 13 in the London region, decreased from **150.4** in week 12 to **125.4** in week 13 in the North region, decreased from **122.2** in week 12 to **97.1** in week 13 in the South region, and decreased from **127.5** in week 12 to **107.7** in week 13 in the Midlands And East region.
- **Upper Respiratory Tract Infections:** decreased from **184.0** in week 12 to **142.1** in week 13 in the London region, decreased from **243.1** in week 12 to **197.5** in week 13 in the North region, decreased from **204.9** in week 12 to **159.1** in week 13 in the South region, and decreased from **245.3** in week 12 to **175.1** in week 13 in the Midlands And East region.
- **COVID-19:** was unchanged at **0.7** in week 12 and **0.7** in week 13 in the London region, decreased from **1.9** in week 12 to **1.2** in week 13 in the North region, decreased from **2.1** in week 12 to **1.0** in week 13 in the South region, and decreased from **1.6** in week 12 to **0.9** in week 13 in the Midlands And East region.

### Comment:

Rates of acute respiratory infections (ARI) have decreased this week and are below the seasonal level for all regions (graph I, page 6). Rates have also decreased for influenza-like illness (ILI) regions (graph A, page 2). Rates of COVID-19 also decreased in most regions (graph G, page 5).


There was a decrease this week in the diagnosis of strep sore throat, scarlatina and peritonsillar abscess though they are above the seasonal average in most of the regions (page 17). Rates of measles and whooping cough have also decreased in most of the regions but also remain above the seasonal average (page 14). Rates of scabies have decreased this week though they are above the seasonal average in all regions (page 15).

This report includes a respiratory virology update. Influenza – particularly Influenza H1N1, SARS-CoV-2 and RSV are the predominant circulating viruses detected by the UK Health Security Agency (UKHSA) Reference Virology Lab. Care is needed in interpreting trend in our data this week due to Easter closures.


## 2023/24 Focus

Please see page 19 for explanatory notes on the data.


### (A) Influenza-like illness: national incidence rate 2023/24 by region



### (B) RCGP/UKHSA Influenza Virology Swab Surveillance 2023/24




**(C) RCGP/UKHSA RSV, Influenza and SARS-CoV-2 Virology Swab Surveillance 2023/24 by viral strain**



The weekly virology samples displayed are offset from the ISO Week (Graph C).  
 \*No specified subtype, or coinfection with H1N1 and H3N2.

**(D) Influenza-like illness: national incidence rate 2023/24 by age band**



**(E) Influenza-like illness: national incidence rate 2023/24 by age band**

This table shows the level of intensity of ILI by age band. MEM thresholds have been calculated separately for each age band - the ranges are shown in the table Threshold levels by age band.

Table 1	42	43	44	45	46	47	48	49	50	51	52	1	2	3	4	5	6	7
1-4yrs	4.0	2.9	2.3	4.3	6.0	3.5	4.5	4.9	5.9	8.4	4.8	4.3	4.9	7.1	11.1	15.0	10.9	9.9
5-14yrs	2.1	1.7	1.4	2.3	2.1	3.2	3.5	4.0	4.3	4.8	2.5	3.0	3.3	5.7	9.2	8.1	7.9	5.5
15-64yrs	3.9	3.7	4.1	4.4	3.9	4.3	5.3	6.3	7.4	8.6	5.4	8.6	9.1	8.4	10.7	9.8	9.7	8.0
65+yrs	2.8	2.7	2.3	2.6	2.1	2.3	2.9	3.1	3.5	6.1	4.5	7.2	7.7	5.5	7.0	8.5	7.5	6.9
All ages	3.5	3.3	3.4	3.9	3.5	3.8	4.6	5.3	6.3	7.7	4.9	7.5	8.0	7.5	9.8	9.6	9.1	7.6


  

	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25
1-4yrs	5.5	6.6	4.7	5.4	3.0	2.0												
5-14yrs	4.9	4.2	3.3	4.2	4.3	2.5												
15-64yrs	7.2	6.2	6.0	6.0	5.4	3.9												
65+yrs	6.0	4.4	4.4	4.2	3.9	2.5												
All ages	6.7	5.7	5.3	5.5	4.9	3.4												

Table 2	Below Threshold <sup>1</sup>	Threshold to Medium <sup>2</sup>	Medium to High <sup>3</sup>	High to Very High <sup>4</sup>	Above Very High <sup>5</sup>
1-4yrs	<8.05	8.05 to 15.57	15.58 to 23.50	23.51 to 28.19	28.20+
5-14yrs	<6.53	6.53 to 15.55	15.56 to 32.18	32.19 to 44.39	44.40+
15-64yrs	<12.23	12.23 to 24.53	24.54 to 45.08	45.09 to 58.99	59.00+
65+yrs	<9.62	9.62 to 16.69	16.70 to 35.98	35.99 to 50.52	50.53+
All Ages	<10.25	10.25 to 21.69	21.70 to 38.77	38.78 to 50.11	50.12+

**Threshold levels**  
<sup>1</sup>Below baseline threshold  
<sup>2</sup>baseline threshold breach to < 40th percentile  
<sup>3</sup>40th to <90th percentile  
<sup>4</sup>90th to <97.5th percentile  
<sup>5</sup>97.5th+ percentile

**(F) Acute Bronchitis and Bronchiolitis: national incidence rate 2023/24 by age band**




**Weekly Influenza-like illness and Acute Bronchitis and Bronchiolitis incidence rates per 100,000 persons**


	Influenza-like illness	Acute Bronchitis and Bronchiolitis		Influenza-like illness	Acute Bronchitis and Bronchiolitis
<1yr	3.4	162.2	London	3.0	2.3
1-4yrs	2.0	11.7	North	3.2	4.6
5-14yrs	2.5	1.4	South	3.7	4.5
15-24yrs	3.7	1.3	Midlands And East	3.5	3.9
25-44yrs	4.0	1.6	National	3.4	3.9
45-64yrs	3.7	2.8			
65-74yrs	2.7	3.2			
75-84yrs	2.3	3.7			
85+yrs	2.0	3.7			
All ages	3.4	3.9			

\*\*The <1yr age band is not presented (Graph F).

**(G) COVID-19: national incidence rate 2023/24 by region**



**(H) COVID-19: national incidence rate 2023/24 by age band**




# 1. Respiratory Infections

**(I) Acute Respiratory Infections (ARI): national incidence rate 2023/24 by region**



**(J) Acute Respiratory Infections (ARI): national incidence rate 2023/24 by age band**




# 1. Respiratory Infections - by region


# 1. Respiratory Infections - by age band




**Influenza-like illness (ILI)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Influenza-like illness (ILI)**  
Weekly incidence (per 100,000 all regions) by age band for 2023/24 compared with 5 year average




**Exacerbations of Chronic Lung Disease (ECLD)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Exacerbations of Chronic Lung Disease (ECLD)**  
Weekly incidence (per 100,000 all regions) by age band for 2023/24 compared with 5 year average



**Lower Respiratory Tract Infections (LRTI)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average



**Lower Respiratory Tract Infections (LRTI)**  
Weekly incidence (per 100,000 all regions) by age band for 2023/24 compared with 5 year average



# 1. Respiratory Infections - by region


# 1. Respiratory Infections - by age band




**Upper Respiratory Tract Infections (URTI)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average



**Upper Respiratory Tract Infections (URTI)**  
Weekly incidence (per 100,000 all regions) by age band for 2023/24 compared with 5 year average




**Exacerbations of Chronic Lung Disease (ECLD) - Asthma Exacerbations**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Exacerbations of Chronic Lung Disease (ECLD) - Asthma Exacerbations**  
Weekly incidence (per 100,000 all regions) by age band for 2023/24 compared with 5 year average



**Exacerbations of Chronic Lung Disease (ECLD) - COPD Exacerbations**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average



**Exacerbations of Chronic Lung Disease (ECLD) - COPD Exacerbations**  
Weekly incidence (per 100,000 all regions) by age band for 2023/24 compared with 5 year average



# 1. Respiratory Infections - by region


# 1. Respiratory Infections - by age band




**Lower Respiratory Tract Infections (LRTI) - Pneumonia**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Lower Respiratory Tract Infections (LRTI) - Pneumonia**  
Weekly incidence (per 100,000 all regions) by age band for 2023/24 compared with 5 year average




**Lower Respiratory Tract Infections (LRTI) - Acute Bronchitis**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Lower Respiratory Tract Infections (LRTI) - Acute Bronchitis**  
Weekly incidence (per 100,000 all regions) by age band for 2023/24 compared with 5 year average



**Lower Respiratory Tract Infections (LRTI) - Bronchiolitis**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average



**Lower Respiratory Tract Infections (LRTI) - Bronchiolitis**  
Weekly incidence (per 100,000 all regions) by age band for 2023/24 compared with 5 year average




# 1. Respiratory Infections - by region


# 1. Respiratory Infections - by age band




**Upper Respiratory Tract Infections (URTI) - Croup**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Upper Respiratory Tract Infections (URTI) - Croup**  
Weekly incidence (per 100,000 all regions) by age band for 2023/24 compared with 5 year average




**Upper Respiratory Tract Infections (URTI) - Tonsillitis/Pharyngitis**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Upper Respiratory Tract Infections (URTI) - Tonsillitis/Pharyngitis**  
Weekly incidence (per 100,000 all regions) by age band for 2023/24 compared with 5 year average



**Upper Respiratory Tract Infections (URTI) - Otitis Media**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Upper Respiratory Tract Infections (URTI) - Otitis Media**  
Weekly incidence (per 100,000 all regions) by age band for 2023/24 compared with 5 year average



# 1. Respiratory Infections - by region


# 1. Respiratory Infections - by age band




**Upper Respiratory Tract Infections (URTI) - Sinusitis**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Upper Respiratory Tract Infections (URTI) - Sinusitis**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average



**Upper Respiratory Tract Infections (URTI) - Laryngitis**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average



**Upper Respiratory Tract Infections (URTI) - Laryngitis**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average



## 2. Water & Food Borne Disorders

5yr Avg   National   North   London   South   Midlands And East


**Infectious Intestinal Disease (ICD10: A00-A09)**  
Weekly incidence (per 100,000 **all ages**) by region  
for 2023/24 compared with 5 year average




**Infectious Intestinal Disease (ICD10: A00-A09)**  
Weekly incidence (per 100,000 **0-4 years**) by region  
for 2023/24 compared with 5 year average



**Non-Infective Enteritis & Colitis (ICD10: K50-K52)**  
Weekly incidence (per 100,000 **all ages**) by region  
for 2023/24 compared with 5 year average




**Viral Hepatitis (ICD10: B15-B19)**  
Weekly incidence (per 100,000 **all ages**) by region  
for 2023/24 compared with 5 year average



### 3. Environmentally Sensitive Disorders

5yr Avg   National   North   London   South   Midlands And East


**Asthma (ICD10: J45-J46)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average



**Disorders of Conjunctiva (ICD10: H10-H13)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Hayfever/Allergic Rhinitis (ICD10: J30)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




## 4. Vaccine Sensitive Disorders

5yr Avg National North London South Midlands And East


**Measles (ICD10: B05)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Mumps (ICD10: B26)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average



**Rubella (ICD10: B06)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Whooping Cough (ICD10: A37)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




## 5. Skin Contagions

**Bullous Dermatoses (ICD10: L10-L14)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Chickenpox (ICD10: B01)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




## 5. Skin Contagions (Continued)

5yr Avg   National   North   London   South   Midlands And East

**Herpes Simplex (ICD10: B00)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Herpes Zoster (ICD10: B02)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average



**Infections of Skin & Subcutaneous Tissue (ICD10: L00-L08)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Scabies (ICD10: B86)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average



**Symptoms involving Skin & Oth Integument Tiss (ICD10: R20-R23)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Impetigo (ICD10: L01)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




## 6. Disorders Affecting the Nervous System

5yr Avg National North London South Midlands And East

**Disorders of The Peripheral Nervous System (ICD10: G50-G64,G70-G72)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average



**Meningitis/Encephalitis(ICD10: A170-A171,A390,A38-A85,A87,G00-G05)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




**Symptoms Involving Nervous & Musculoskeletal (ICD10: R25-R29)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average



## 7. Genitourinary System Disorders

**Urinary Tract Infection/Cystitis (ICD10: N30,N390)**  
Weekly incidence (per 100,000 all ages) by region for 2023/24 compared with 5 year average




## 8. Other Disorders

■ 5yr Avg   
 ■ National   
 ■ North   
 ■ London   
 ■ South   
 ■ Midlands And East

**Strep Sore Throat, Scarlatina and Peritonsillar Abscess (ICD10: A38,J020,J36)**  
 Weekly incidence (per 100,000 all ages) by region  
 for 2023/24 compared with 5 year average



**Infectious Mononucleosis (ICD10: B27)**  
 Weekly incidence (per 100,000 all ages) by region  
 for 2023/24 compared with 5 year average



## 8. Tabular Summary by Disease

Disease Name	Week beginning Week ending		25/03/2024 31/03/2024		18/03/2024 24/03/2024		11/03/2024 17/03/2024		04/03/2024 10/03/2024	
	Rate	Numer	Rate	Numer	Rate	Numer	Rate	Numer	Rate	Numer
Acute Bronchitis	2.2	372	2.5	438	2.9	496	2.8	490		
Acute respiratory infections (ARI)	271.2	45,975	346.8	59,744	345.3	60,008	332.3	58,226		
Allergic Rhinitis	5.8	979	6.8	1,175	5.8	1,011	6.0	1,057		
Asthma	9.2	1,563	11.7	2,012	12.2	2,114	11.7	2,052		
Bronchiolitis	1.8	299	2.1	367	2.4	419	2.3	399		
Bullous Dermatoses	0.1	25	0.2	31	0.2	35	0.2	34		
Chickenpox	2.7	461	2.8	477	3.3	572	2.7	479		
Conjunctival Disorders	13.7	2,316	16.6	2,866	16.1	2,791	17.1	2,993		
COVID-19	1.0	169	1.6	284	1.7	295	1.6	278		
Croup	1.7	284	2.2	375	2.5	426	2.6	449		
ECLD - Asthma exacerbations	6.4	1,089	7.9	1,368	7.9	1,378	7.2	1,254		
ECLD - COPD exacerbations	5.4	912	6.2	1,074	6.3	1,091	6.4	1,117		
Exacerbations of chronic lung disease	12.0	2,033	14.4	2,480	14.3	2,491	13.7	2,395		
Herpes Simplex	2.3	384	2.6	454	2.9	507	2.6	449		
Herpes Zoster	3.9	665	4.8	823	4.5	790	4.7	828		
Impetigo	3.1	519	3.1	529	3.4	591	3.5	605		
Infectious Intestinal Diseases	5.1	860	6.6	1,145	7.2	1,246	6.6	1,156		
Infectious Mononucleosis	0.3	51	0.4	65	0.4	61	0.3	58		
Influenza-like illness	3.4	575	4.9	846	5.5	950	5.3	935		
Laryngitis	1.1	190	1.5	254	1.5	260	1.5	261		
Lower respiratory tract infections	98.8	16,750	120.4	20,749	119.4	20,749	116.6	20,434		
Measles	0.1	22	0.1	24	0.2	40	0.2	34		
Meningitis and Encephalitis	0.1	13	0.2	28	0.1	18	0.2	27		
Mumps	0.1	12	0.1	16	0.1	14	0.1	20		
Non-infective Enteritis and Colitis	2.1	349	2.6	441	2.6	450	2.7	469		
Otitis Media	21.4	3,625	29.9	5,155	27.3	4,743	25.9	4,545		
Peripheral Nervous Disease	13.7	2,326	18.4	3,168	17.7	3,080	18.9	3,314		
Pneumonia	3.0	517	4.3	736	4.2	733	4.1	711		
Rubella	0.0	2	0.0	0	0.0	1	0.0	0		
Scabies	2.2	365	2.5	435	3.3	568	2.8	488		
Sinusitis	17.3	2,941	20.6	3,544	21.0	3,651	20.5	3,586		
Skin and Subcutaneous Tissue Infections	69.1	11,721	83.2	14,335	81.2	14,110	82.5	14,451		
Strep Throat and Peritonsillar Abscess	4.0	683	5.5	952	5.5	957	4.9	858		
Symptoms involving musculoskeletal	11.2	1,905	14.9	2,563	15.0	2,599	15.1	2,646		
Symptoms involving Skin and Integument Tissues	104.0	17,635	130.0	22,402	125.4	21,790	127.8	22,389		
Tonsillitis/Pharyngitis	37.1	6,289	47.5	8,187	49.4	8,581	46.0	8,063		
Upper respiratory tract infections	169.0	28,653	220.0	37,900	221.5	38,499	211.9	37,128		
Urinary Tract Infections	16.3	2,760	19.8	3,405	19.9	3,454	21.0	3,682		
Viral Hepatitis	0.1	20	0.2	42	0.2	33	0.4	64		
Whooping Cough	0.5	78	0.7	114	0.7	113	0.4	78		
<b>Practice Count</b>		<b>1,654</b>		<b>1,684</b>		<b>1,708</b>		<b>1,723</b>		
<b>Denom</b>		<b>16,953,027</b>		<b>17,228,234</b>		<b>17,379,672</b>		<b>17,520,900</b>		

## FURTHER INFORMATION:

### **About the report**

#### **Focus**

The first two pages of data within this report focus on influenza-like illness and virology data, in order to provide information about seasonal influenza and early warnings of any epidemic.

#### **Rate calculation**

Each weekly incidence rate is presented per 100,000 population. All presentations are for males and females, and for all age bands, unless otherwise stated.

The denominator used for this report is taken from our most recent extract of data from GP practice systems, and includes all patients currently registered with eligible practices. The denominator varies week-on-week as patients register and deregister; it may also be the case that all patients from an individual practice are excluded because of problems with the data extraction from that practice in a specific week. As stated above, patients who have withheld consent for data-sharing are excluded.

In addition to the national rate, we present data for the four NHS England regions: North; Midlands and East; South; and London.

#### **Five-year averages**

Weekly rates are set against a five-year average (navy blue lines), previously we reported against a ten-year average. The change to a five-year average was made because longer-term trends in the incidence of disease have led to weekly rates for certain diseases becoming increasingly divergent from their ten-year average. The use of five-year averages lessens this effect and enables more meaningful comparison.

#### **Threshold calculation for influenza-like illness (ILI)**

We are now using the Moving Epidemic Method (MEM) to calculate threshold and intensity levels for influenza-like illness (Graph A, page 2 and Table E, page 4 of this report). MEM works by identifying seasonal epidemic peaks and then calculates thresholds and intensity levels based on the pre and post epidemic values. This allows us to report the severity of ILI against multiple thresholds, rather than a simple comparison with the five-year average as the wide variation in ILI year on year, especially during the seasonal peak, makes the average less representative.

In addition to the All Ages thresholds, we have also calculated thresholds for four age bands: those aged 1-4, 5-14, 15-64 and those aged 65 and over. ILI incidence rates vary among different age bands, and the age-specific thresholds allow us to highlight epidemics where ILI disproportionately affects a particular age band.

This methodology is used by the European Centre for Disease Prevention and Control to standardise reporting of influenza activity across Europe, and is also in use by the UK Health Security Agency. Full details of the methodology can be found in: Vega *et al.* (2012) Influenza surveillance in Europe: establishing epidemic thresholds by the moving epidemic method. *Influenza and Other Respiratory Viruses* 7(4), 546–558.

Both the *all-ages* thresholds and the *age-specific* thresholds are shown in Table E, page 4. Five years of data were used for *all-ages* and *age-specific* thresholds calculation (winter seasons 2015/16, 2016/17, 2017/18, 2018/19 and 2022/23, excluding 2019/20, 2020/21 and 2021/22).

## About the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC)

### **Acknowledgement:**

Staff from the Data Science department at the National Physical Laboratory (<https://www.npl.co.uk/data-science>) assisted in the provision of and extension of the primary care national surveillance reports during the 2020 SARS-CoV-2 pandemic; as well as adding resilience.

### **What we do**

The RCGP RSC was established in 1957, with the current name in use since 2009. The Centre is an internationally renowned source of information, analysis and interpretation concerning the onset, patterns, prevalence and trends over time of morbidity in primary care. The RSC is an active research and surveillance unit that collects and monitors data; its most important research is the surveillance of influenza and the monitoring of vaccine effectiveness.

The RSC data and analytics hub is housed at the Oxford-Royal College of General Practitioners Research and Surveillance Centre.

Further information about the RSC can be found on our website:

<http://www.rcgp.org.uk/rsc>

### **Our data extraction process and information governance**

Data are extracted twice weekly from practice systems by Magentus data management and EMIS-X Analytics (EXA) on the RCGP's behalf. Patients who have withheld consent for data sharing are excluded from the extraction process.

Data are pseudonymised as close to source as possible. Data are held on secure servers at the RCGP data and analytics hub at the Oxford-Royal College of General Practitioners Research and Surveillance Centre. Both Magentus data management and the University of Oxford are Registered and compliant with the Data Protection Act and fully compliant with all relevant NHS Digital data information governance best practice.

### **What the data is used for**

The RCGP RSC has been providing reports weekly about health and disease, called the Weekly Returns Service (WRS) since 1964. The WRS monitors the number of patients consulting with new episodes of illness classified by diagnosis in England and provides weekly incidence rates per 100,000 population for these new episodes of illness. It is the key primary care element of the national disease monitoring systems run by the UK Health Security Agency. The bulletin can be found at the following URL:

<https://www.gov.uk/government/collections/syndromic-surveillance-systems-and-analyses>

In addition to the WRS, the data is used for other research studies. Any other uses of the data for research follow ethical approval or agreement from NIHR proportionate review, and where relevant Health Research Authority Confidential Advisory Group advice that further approval is not needed. Full details can be found on our website:

<http://www.rcgp.org.uk/rsc>

### **For further information**

For further information about the work of the RSC, or if you would like to be included on our email notification list, please contact:

RCGP Research & Surveillance Centre  
Policy, Research and Campaigns  
Royal College of General Practitioners  
30 Euston Square, London, NW1 2FB  
Tel: switchboard 020 3188 7400

University of Oxford  
Nuffield Department of Primary Care Health  
Sciences  
Eagle House  
7 Walton Well Road  
Oxford OX2 6ED

Director: Professor Simon de Lusignan

[MedicalDirectorRSC@rcgp.org.uk](mailto:MedicalDirectorRSC@rcgp.org.uk)

